Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chemaphor names new CEO
Dr Dick holds a veterinary degree with advanced training in infectious diseases and immunology. He has held positions of responsibility over nearly 20 years with two multinational pharmaceutical
Dr Dick holds a veterinary degree with advanced training in infectious diseases and immunology. He has held positions of responsibility over nearly 20 years with two multinational pharmaceutical
Mr Reid will be responsible for OraSure’s international sales efforts for the company’s diagnostic businesses. Mr Reid will report to Douglas Michels, OraSure’s president and CEO. Most recently
In addition to assuming overall management of the company and its European operations, Mr Ginsberg will assume responsibility of North American operations from Kenneth Borow, who is no
Applications for marketing authorizations were filed in the 15 member states involved in the decentralized procedure. The launch of Glucophage powder for oral solution in sachet will be
The primary objective of this first human clinical study on ImVisioN’s lead product IVN201 for the treatment of cat dander allergies will be product safety, but the study
Salt Creek Medical Device Development (Salt Creek Medical), a medical device company ‘generator’, provided all of the financing through its venture fund, Salt Creek Fund I. The company
Under terms of the agreement, Handok will receive marketing and distribution rights to all cancer indications for Amplimexon in Korea and will pay AmpliMed an up-front fee plus
PRT-201 is being investigated for its ability to improve vascular access in patients currently on or being prepared for hemodialysis. The fast track designation is intended to facilitate
Fresenius Kabi has said that the acquisition is an important step in its growth strategy. Through APP, Fresenius Kabi enters the US pharmaceuticals market and is likely to
The Serdaxin Phase II trial is a randomized, double-blind, placebo-controlled parallel study for the treatment of major depressive disorders. It is a multi-center trial with preliminary data in